131 related articles for article (PubMed ID: 15466383)
1. Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.
Prabhu R; Khalap N; Burioni R; Clementi M; Garry RF; Dash S
Am J Pathol; 2004 Oct; 165(4):1163-73. PubMed ID: 15466383
[TBL] [Abstract][Full Text] [Related]
2. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.
Chandra PK; Hazari S; Poat B; Gunduz F; Prabhu R; Liu G; Burioni R; Clementi M; Garry RF; Dash S
Virol J; 2010 Jun; 7():118. PubMed ID: 20529250
[TBL] [Abstract][Full Text] [Related]
3. Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.
Chen M; Sällberg M; Sönnerborg A; Jin L; Birkett A; Peterson D; Weiland O; Milich DR
Hepatology; 1998 Jul; 28(1):219-24. PubMed ID: 9657115
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies.
Artsaenko O; Tessmann K; Sack M; Häussinger D; Heintges T
J Gen Virol; 2003 Sep; 84(Pt 9):2323-2332. PubMed ID: 12917452
[TBL] [Abstract][Full Text] [Related]
5. Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity.
Phalaphol A; Thueng-In K; Thanongsaksrikul J; Poungpair O; Bangphoomi K; Sookrung N; Srimanote P; Chaicumpa W
J Virol Methods; 2013 Dec; 194(1-2):289-99. PubMed ID: 24036073
[TBL] [Abstract][Full Text] [Related]
6. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
7. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity.
Kim DW; Gwack Y; Han JH; Choe J
Biochem Biophys Res Commun; 1995 Oct; 215(1):160-6. PubMed ID: 7575585
[TBL] [Abstract][Full Text] [Related]
8. [The combined application of nucleotide and amino acid sequences of NS3 hepatitis C virus protein, DNA encoding granulocyte macrophage colony-stimulating factor and inhibitor of regulatory T cells induces effective immune response against hepatitis C virus].
Masalova OV; Lesnova EI; Shingarova LN; Tunitskaia VL; Ulanova TI; Burkov AN; Kushch AA
Mol Biol (Mosk); 2012; 46(3):525-34. PubMed ID: 22888642
[TBL] [Abstract][Full Text] [Related]
9. Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3.
Manabe S; Fuke I; Tanishita O; Kaji C; Gomi Y; Yoshida S; Mori C; Takamizawa A; Yosida I; Okayama H
Virology; 1994 Feb; 198(2):636-44. PubMed ID: 8291245
[TBL] [Abstract][Full Text] [Related]
10. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.
Hwang B; Cho JS; Yeo HJ; Kim JH; Chung KM; Han K; Jang SK; Lee SW
RNA; 2004 Aug; 10(8):1277-90. PubMed ID: 15247433
[TBL] [Abstract][Full Text] [Related]
11. Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA.
Banerjee R; Dasgupta A
J Virol; 2001 Feb; 75(4):1708-21. PubMed ID: 11160669
[TBL] [Abstract][Full Text] [Related]
12. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
[TBL] [Abstract][Full Text] [Related]
13. Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody.
Mondelli MU; Cerino A; Boender P; Oudshoorn P; Middeldorp J; Fipaldini C; La Monica N; Habets W
J Virol; 1994 Aug; 68(8):4829-36. PubMed ID: 7518528
[TBL] [Abstract][Full Text] [Related]
14. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Howe AY; Chase R; Taremi SS; Risano C; Beyer B; Malcolm B; Lau JY
Protein Sci; 1999 Jun; 8(6):1332-41. PubMed ID: 10386883
[TBL] [Abstract][Full Text] [Related]
15. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.
Mansilla C; Gorraiz M; Martinez M; Casares N; Arribillaga L; Rudilla F; Echeverria I; Riezu-Boj JI; Sarobe P; Borrás-Cuesta F; Prieto J; Lasarte JJ
J Hepatol; 2009 Sep; 51(3):520-7. PubMed ID: 19596480
[TBL] [Abstract][Full Text] [Related]
16. Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase.
Tessmann K; Erhardt A; Häussinger D; Heintges T
J Virol Methods; 2002 May; 103(1):75-88. PubMed ID: 11906735
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein.
Zhang ZX; Lazdina U; Chen M; Peterson DL; Sällberg M
Clin Diagn Lab Immunol; 2000 Jan; 7(1):58-63. PubMed ID: 10618278
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus nonstructural protein NS3 unfolds viral G-quadruplex RNA structures.
Belachew B; Gao J; Byrd AK; Raney KD
J Biol Chem; 2022 Nov; 298(11):102486. PubMed ID: 36108740
[TBL] [Abstract][Full Text] [Related]
19. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
[TBL] [Abstract][Full Text] [Related]
20. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets.
Blight KJ; Kolykhalov AA; Reed KE; Agapov EV; Rice CM
Antivir Ther; 1998; 3(Suppl 3):71-81. PubMed ID: 10726057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
